Chimeric Polypeptides Target Bacterial Cell Walls
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial treatments face challenges due to the emergence of antibiotic-resistant bacteria, and existing methods require rapid bacterial growth to be effective, limiting their utility in controlling bacterial pathogenicity and growth.
Innovation Solution
Development of chimeric polypeptides combining tail-associated murein-degrading enzymes (TAMEs) from phages with cell wall binding domains, such as ORF56 and ORF49, which exhibit enhanced bactericidal activity and stability, allowing for targeted degradation of bacterial cell walls.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chimeric polypeptides combining TAMEs with cell wall binding domains are developed, then bactericidal efficiency is significantly increased, but device complexity increases
Solution Approach 1:
The patent combines two functional domains into a single chimeric polypeptide: the tail-associated murein-degrading enzyme (TAME) domain for cell wall degradation and the cell wall binding domain (CBD) for target recognition and binding. This merging of functions into one molecule increases bactericidal efficiency by ensuring both specific binding and effective degradation at the target site, while the modular nature of the chimera allows for standardized construction methods that can mitigate complexity management.
Solution Approach 2:
The chimeric polypeptide represents a composite biological molecule combining domains from different functional origins. The TAME domain provides enzymatic activity for peptidoglycan degradation, while the CBD domain provides specific binding to cell wall components. This composite structure integrates multiple functions that work synergistically to achieve enhanced bactericidal activity against target bacteria.
2Productivity
If phage endolysins are used to kill bacteria, then bacterial growth is reduced, but the treatment requires rapid bacterial growth to be effective
Solution Approach 1:
The invention extracts the bactericidal function from the context of rapid bacterial replication that traditional phage therapy requires. By using isolated TAME enzymes delivered via chimeric polypeptides, the system achieves bactericidal activity through direct cell wall degradation without depending on bacterial replication cycles. This extraction of the killing mechanism from the replication-dependent context enables effectiveness against slow-growing and stationary-phase bacteria.
Solution Approach 2:
The chimeric polypeptide acts as an intermediary delivery system that brings the TAME enzyme directly to the bacterial cell wall target. The cell wall binding domain serves as a mediator that guides the enzymatic domain to the appropriate target site, ensuring efficient delivery and action of the bactericidal agent independent of bacterial growth rate. This intermediary system enables precise targeting and effective killing regardless of bacterial metabolic state.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric polypeptides demonstrate significantly increased bactericidal efficiency and stability, effectively reducing bacterial growth and pathogenicity across multiple bacterial strains, including methicillin-resistant Staphylococcus species, with potential applications in treating infections and disinfecting surfaces.
Implementation Method 1
tail-associated murein-degrading enzymes (TAMEs) from phages with cell wall binding domains... targeted degradation of bacterial cell walls
Implementation Method 2
Phages kill cells by infecting, replicating, and then lysing the host cell
Data Source
Figure 1
Figure 1
AI summary
The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.